BMRN:NGS-BioMarin Pharmaceutical Inc.

EQUITY | Biotechnology | Nasdaq Global Select

Last Closing

USD 97.69

Change

+0.18 (+0.18)%

Market Cap

USD 14.69B

Volume

1.29M

Analyst Target

USD 120.30
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Biomarin Pharmaceutical Inc develops and commercializes pharmaceuticals for serious diseases and medical conditions. Its product portfolio is comprised of five product candidates Naglazyme, Kuvan, Aldurazyme, VIMIZIM and Firdapse.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2019-01-18 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
VRTX Vertex Pharmaceuticals Inc

+0.38 (+0.10%)

USD 107.38B
REGN Regeneron Pharmaceuticals Inc

-7.20 (-0.80%)

USD 106.98B
MRNA Moderna Inc

-1.44 (-1.39%)

USD 39.68B
BNTX BioNTech SE

-0.23 (-0.27%)

USD 21.93B
ARGX argenx NV ADR

-7.79 (-2.13%)

USD 21.60B
GMAB Genmab AS

-0.20 (-0.70%)

USD 19.78B
ALNY Alnylam Pharmaceuticals Inc

-0.16 (-0.11%)

USD 18.55B
RPRX Royalty Pharma Plc

+0.28 (+1.01%)

USD 18.18B
BGNE BeiGene Ltd

+0.10 (+0.08%)

USD 16.99B
INCY Incyte Corporation

+0.10 (+0.19%)

USD 12.79B

ETFs Containing BMRN

GDOC Goldman Sachs ETF Trust 2.99 % 0.00 %

-0.24 (-0.42%)

USD 0.03B
BTEC:SW iShares Nasdaq US Biotech.. 1.76 % 0.00 %

-0.03 (-0.42%)

USD 0.46B
BIB ProShares Ultra Nasdaq Bi.. 0.00 % 0.95 %

-0.94 (-0.42%)

USD 0.10B
BIS ProShares UltraShort Nasd.. 0.00 % 0.95 %

+0.41 (+-0.42%)

USD 3.90M
LABD Direxion Daily S&P Biotec.. 0.00 % 1.00 %

+0.44 (+-0.42%)

USD 0.19B
LABS 0.00 % 0.45 %

N/A

N/A
PBE Invesco Dynamic Biotechno.. 0.00 % 0.57 %

-0.94 (-0.42%)

USD 0.24B
FCVT First Trust SSI Strategic.. 0.00 % 0.95 %

-0.11 (-0.42%)

USD 0.08B
EASI 0.00 % 0.75 %

N/A

N/A
BTEC:LSE iShares Nasdaq US Biotech.. 0.00 % 0.00 %

-0.04 (-0.42%)

USD 0.49B
BTEK:LSE iShares Nasdaq US Biotech.. 0.00 % 0.00 %

-0.04 (-0.42%)

USD 0.49B
BIGT:LSE L&G Pharma Breakthrough U.. 0.00 % 0.00 %

-1.55 (-0.42%)

USD 0.02B
BIOT:LSE L&G PHARMA BREAKTHROUGH G.. 0.00 % 0.00 %

N/A

USD 8.18M
BTEE:LSE iShares Nasdaq US Biotech.. 0.00 % 0.00 %

-0.04 (-0.42%)

USD 0.49B
UBIO 0.00 % 0.95 %

N/A

N/A
ZBIO 0.00 % 0.95 %

N/A

N/A
XS2D:LSE Xtrackers S&P 500 2x Leve.. 0.00 % 0.00 %

+0.74 (+-0.42%)

USD 0.29B
2B70:F iShares NASDAQ US Biotech.. 0.00 % 0.00 %

-0.05 (-0.42%)

USD 0.52B
DBPG:F Xtrackers - S&P 500 2x Le.. 0.00 % 0.00 %

-1.26 (-0.42%)

USD 0.32B
ETLI:F Legal & General UCITS ETF.. 0.00 % 0.00 %

-0.09 (-0.42%)

USD 0.02B
2B70:XETRA iShares Nasdaq US Biotech.. 0.00 % 0.00 %

-0.05 (-0.42%)

USD 0.52B
DBPG:XETRA Xtrackers S&P 500 2x Leve.. 0.00 % 0.00 %

+0.92 (+-0.42%)

USD 0.32B
ETLI:XETRA L&G Pharma Breakthrough U.. 0.00 % 0.00 %

-0.02 (-0.42%)

USD 0.02B
BIOT 0.00 % 0.00 %

N/A

N/A
BMED BlackRock Future Health E.. 0.00 % 0.00 %

-0.21 (-0.42%)

USD 4.14M
IBBQ Invesco Nasdaq Biotechnol.. 0.00 % 0.00 %

-0.23 (-0.42%)

USD 0.03B
THNZ:XETRA L&G Global Thematic ESG E.. 0.00 % 0.00 %

+0.03 (+-0.42%)

USD 4.28M
BIOT:SW L&G Pharma Breakthrough U.. 0.00 % 0.00 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange (Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 14.73% 53% F 73% C
Dividend Return N/A N/A N/A N/A F
Total Return 14.73% 53% F 73% C
Trailing 12 Months  
Capital Gain 8.81% 77% C+ 80% B-
Dividend Return N/A N/A N/A N/A F
Total Return 8.81% 76% C+ 78% C+
Trailing 5 Years  
Capital Gain 33.00% 76% C+ 61% D-
Dividend Return N/A N/A N/A N/A F
Total Return 33.00% 75% C 56% F
Average Annual (5 Year Horizon)  
Capital Gain 12.82% 61% D- 65% D
Dividend Return 12.82% 60% D- 62% D
Total Return N/A N/A N/A N/A F
Risk Return Profile  
Volatility (Standard Deviation) 41.56% 56% F 27% F
Risk Adjusted Return 30.84% 66% D+ 47% F
Market Capitalization 14.69B 98% N/A 97% N/A

Key Financial Ratios

  Ratio vs. Industry/Classification (Biotechnology) Ratio vs. Market (Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio -139.56 99% 98%
Price/Book Ratio 6.02 22% 17%
Price / Cash Flow Ratio -305.28 100% 100%
Price/Free Cash Flow Ratio -111.01 99% 97%
Management Effectiveness  
Return on Equity -4.38% 84% 38%
Return on Invested Capital -4.69% 86% 41%
Return on Assets -2.69% 90% 40%
Debt to Equity Ratio 41.50% 30% 52%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative earnings

The company had negative total earnings in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.